RTI Biologics, Inc. (RTIX) Tops Q1 EPS by 2c; Boosts Outlook

RTI Biologics, Inc. (NASDAQ: RTIX) reported Q1 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $60.7 million versus the consensus estimate of $55.4 million.

RTI Biologics, Inc. sees FY2014 EPS of $0.07-$0.09, versus prior guidance of $0.06-$0.08 and the consensus of $0.07. RTI Biologics, Inc. sees FY2014 revenue of $248-253 million, versus prior guidance of $245-250 million and the consensus of $236.80 million.

For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Kimberly-Clark (KMB) Tops Q1 EPS by 38c; updates outlook
• Webster Financial (WBS) Misses Q1 EPS by 6c